Adma is the abbreviation for asymmetric dimethylarginine. It is a naturally occurring component of human blood plasma, and it can inhibit a compound that is capable of dilating blood vessels.
Diabetes has been identified as a risk factor for heart disease. A recent study by Steno Diabetes Center, Gentofte, Denmark found that people with Type-1 diabetes and kidney disease are at higher risk of heart-related events and progressive kidney disease because of the high blood levels of Adma.
In fact, previous research has already shown that high blood levels of Adma do reduce the ability of the blood vessels to widen, and this would lead to an increased risk of heart and blood vessel disease.
In the new study, researchers investigated how the value of Adma could be related to heart and kidney events in 397 Type-1 diabetic patients with diabetic kidney disease and 175 diabetic controls without kidney disease.
For patients with diabetics with kidney disease, those with Adma levels above the median were more likely (43.4 percent) to suffer a fatal or nonfatal major cardiovascular event such as heart attack than those with Adma levels below the median (19.4 percent).
Moreover, patients with Adma levels above the median also experienced a faster decline in their kidney function than those with lower Adma levels. Meanwhile, the researchers also indicated that patients with higher Adma levels were 3.2 times more likely to develop end-stage renal disease (the most advanced form of kidney disease) than those with lower levels of Adma.
The overall mortality was found to be 67 percent higher for patients with higher Adma levels than those with lower Adma levels.
If other future studies could also confirm similar finding, then Adma might be used by doctors to identify relevant Type-1 diabetic who are at particularly high risk of adverse heart and kidney-related events.
Diabetes has been identified as a risk factor for heart disease. A recent study by Steno Diabetes Center, Gentofte, Denmark found that people with Type-1 diabetes and kidney disease are at higher risk of heart-related events and progressive kidney disease because of the high blood levels of Adma.
In fact, previous research has already shown that high blood levels of Adma do reduce the ability of the blood vessels to widen, and this would lead to an increased risk of heart and blood vessel disease.
In the new study, researchers investigated how the value of Adma could be related to heart and kidney events in 397 Type-1 diabetic patients with diabetic kidney disease and 175 diabetic controls without kidney disease.
For patients with diabetics with kidney disease, those with Adma levels above the median were more likely (43.4 percent) to suffer a fatal or nonfatal major cardiovascular event such as heart attack than those with Adma levels below the median (19.4 percent).
Moreover, patients with Adma levels above the median also experienced a faster decline in their kidney function than those with lower Adma levels. Meanwhile, the researchers also indicated that patients with higher Adma levels were 3.2 times more likely to develop end-stage renal disease (the most advanced form of kidney disease) than those with lower levels of Adma.
The overall mortality was found to be 67 percent higher for patients with higher Adma levels than those with lower Adma levels.
If other future studies could also confirm similar finding, then Adma might be used by doctors to identify relevant Type-1 diabetic who are at particularly high risk of adverse heart and kidney-related events.
No comments:
Post a Comment